Lessons Learned from Open-label Deep Brain Stimulation for Tourette Syndrome: Eight Cases over 7 Years
Motlagh MG, Smith ME, Landeros-Weisenberger A, Kobets AJ, King RA, Miravite J, de Lotbinière AC, Alterman RL, Mogilner AY, Pourfar MH, Okun MS, Leckman JF. Lessons Learned from Open-label Deep Brain Stimulation for Tourette Syndrome: Eight Cases over 7 Years. Tremor And Other Hyperkinetic Movements 2013, 3: 03. PMID: 24255802, PMCID: PMC3822402, DOI: 10.5334/tohm.126.Peer-Reviewed Original ResearchDeep brain stimulationYale Global Tic Severity ScaleTourette syndromeBrain targetsBrain stimulationMedication-refractory Tourette syndromeHomogenous clinical entityOpen-label experienceRefractory Gilles deSerious adverse eventsSelection of patientsRisk of surgeryMidline thalamic nucleiTic Severity ScalePatient-specific outcomesAdverse eventsClinical improvementPostoperative improvementClinical entityGlobus pallidusDBS patientsThalamic nucleiInclusion criteriaSeverity ScaleClinical experienceLONG‐TERM OUTCOME IN ADULTS WITH OBSESSIVE‐COMPULSIVE DISORDER
Bloch MH, Green C, Kichuk SA, Dombrowski PA, Wasylink S, Billingslea E, Landeros‐Weisenberger A, Kelmendi B, Goodman WK, Leckman JF, Coric V, Pittenger C. LONG‐TERM OUTCOME IN ADULTS WITH OBSESSIVE‐COMPULSIVE DISORDER. Depression And Anxiety 2013, 30: 716-722. PMID: 23532944, PMCID: PMC3932438, DOI: 10.1002/da.22103.Peer-Reviewed Original ResearchConceptsLong-term outcomesObsessive-compulsive disorderEvidence-based treatmentsAdult OCD patientsLong-term clinical outcomesSymptom severitySerotonin reuptake inhibitor medicationsOCD patientsPlacebo-controlled trialSerotonin reuptake inhibitorsReuptake inhibitor medicationsPercent of subjectsInitial responseSymptom dimensionsLater symptom severityOCD symptomsSignificant OCD symptomsOCD symptom dimensionsAdult patientsClinical characteristicsClinical improvementEligible subjectsPartial respondersInhibitor medicationReuptake inhibitors